AbbVie (ABBV) announced that Canada's Drug Agency has recommended that VRAYLAR be reimbursed with conditions, for the treatment of schizophrenia in adults. VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada in 2022.
"This important milestone for VRAYLAR speaks to AbbVie's commitment to not only bring new therapeutic options for severe mental illness to Canada, but to work with governments, clinicians and community stakeholders to reduce disparities and make these medicines accessible to all Canadian patients," said Rami Fayed, Vice President and General Manager, AbbVie Canada.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.